LDLR and breast cancer: Since the vast majority of included patients in this trial had ER-positive breast cancer, in line with the MCF-7 cell line used for the in vitro experiments, it can be questioned if the upregulation of LDLR seen in this study is limited to ER-positive breast cancer, which needs to be further investigated in future trials.